We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cladribine Tablets

News List

Cladribine Tablets Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland firstwordpharma
March 26, 2019
Merck KGaA, Darmstadt, Germany, a leading science and technology company……
Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets) worldpharmanews
October 12, 2018
Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, German
Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS cphi-online
June 27, 2017
Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical trials.